Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Products
  • Science & Pipeline
  • Patients & Families
  • Medical Professionals
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

PRESS RELEASES

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

PRESS RELEASES

Press Releases
Date Title
Sep 28, 2023 Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Sep 25, 2023 Tenapanor for Hyperphosphatemia Approved in Japan
Sep 11, 2023 Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
Sep 8, 2023 Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 7, 2023 Ardelyx, Inc. Reports Employment Inducement Grants
Aug 2, 2023 Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
Jul 27, 2023 Ardelyx, Inc. Reports Employment Inducement Grants
Jul 26, 2023 Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Jul 20, 2023 Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Jul 13, 2023 Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2023 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS